 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CD19-PD1-CART cell / Chinese PLA General Hospital
New P2 trial, CAR T-Cell Therapy: Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov) - Nov 14, 2019
P2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital